Clinical Trial

PTCY Plus uhCG/EGF for Graft Versus Host Disease Prophylaxis

Recruiting Phase 1
View on ClinicalTrials.gov →
Summary
So this a Phase I study with primary objective to determine the feasibility and safety of combining post-transplant cyclophosphamide and urinary-derived human chorionic gonadotropin and epidermal growth factor (uhCG/EGF) as graft versus host disease prophylaxis in stem cell transplant with MMUDs Secondary objectives are to determine the incidence acute and chronic GVHD, progression-free survival , and overall survival
Protocol Amendment History 8 amendments
This ClinicalTrials.gov record has been amended 8 times since 2021-05-10; most recent amendment 2026-02-23.
Status change: Not Yet Recruiting → Recruiting 2021-12-23
Trial Details
NCT Number NCT04886726
Lead Sponsor Henry Ford Health System
Conditions Graft Versus Host Disease
Enrollment 18 participants
Start Date 2021-12-23
Primary Completion 2028-11-30 (estimated)
Study Completion 2028-11-30 (estimated)
Updated on ClinicalTrials.gov 2026-02-24